BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the stocks with explosive growth potential. On February 24, BridgeBio Pharma reported a transformative full-year 2025, marked by a surge in total revenue ...

- As of August 1, 2025, 3,751 unique patient prescriptions have been written by 1,074 unique prescribers, representing an accelerating launch driven by strong month over month growth in the crucial ...

BridgeBio Pharma Inc (BBIO) reports robust financial performance and strategic progress, driven by Atruby's market success and promising Phase 3 results.

- As of February 17, 2025, 1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval - Attruby (acoramidis), the first and only near-complete TTR ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. BridgeBio’s recently ...

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. The third stock on our list is BridgeBio Pharma, Inc. TheFly reported on January 8 that Truist raised its price target on BBIO to ...

No-moat BridgeBio reported fourth-quarter results that were largely in line with our expectations. Investors have reacted positively to BridgeBio’s recent developments and have sent the stock up 30% ...

Post the presentation at the 2025 JPMorgan Healthcare Conference by BridgeBio (BBIO), JPMorgan analyst Anupam Rama says the firm was “VERY encouraged” by initial Attruby metrics and notes that there ...

- $36.7 million in first full quarter of U.S. Attruby™ net product revenue and as of April 25, 2025, 2,072 unique patient prescriptions written by 756 unique prescribers - Observational run-in study ...